Transplant reno-vascular stenoses associated with early erythropoeitin use

Clinical Transplantation

Volumn 21, Issue 5, 2007, Pages 597-608

  Nagarajan, Suja ^a   Mansfield, Elaine ^a   Hsieh, Sue ^a   Liu, Rosa ^a   Hsieh, Frank ^b   Li, Li ^a   Salvatierra Jr , Oscar ^a   Sarwal, Minnie M ^a  

^a STANFORD UNIVERSITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Anemia; Hypertension; Microarray; Renal transplantation; Reno; Steroid Avoidance; Vascular Stenoses

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; CLOPIDOGREL; COMPLEMENTARY DNA; ERYTHROPOIETIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS;

ADOLESCENT; ADULT; ANEMIA; ANGIOPLASTY; ARTICLE; BLOOD ANALYSIS; CHILD; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA MICROARRAY; DRUG WITHDRAWAL; EARLY INTERVENTION; GENE EXPRESSION PROFILING; GRAFT REJECTION; HUMAN; INCIDENCE; INFANT; KIDNEY ARTERY STENOSIS; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RENOVASCULAR DISEASE; RENOVASCULAR HYPERTENSION; RISK FACTOR;

ADOLESCENT; CHILD; CONSTRICTION, PATHOLOGIC; ERYTHROPOIETIN, RECOMBINANT; GENETIC PREDISPOSITION TO DISEASE; HEMATINICS; HUMANS; HYPERTENSION, RENOVASCULAR; KIDNEY TRANSPLANTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RETROSPECTIVE STUDIES;

EID: 34548660438     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2007.00694.x     Document Type: Article

References (46)

1. Englund M, Berg U, Tyden G. A longitudinal study of children who received renal transplants 10-20 years ago. Transplantation 2003: 76: 311.
2. Sarwal MM, Vidhun JR, Alexander SR, Satterwhite T, Millan M, Salvatierra O Jr. Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation. Transplantation 2003: 76: 1331.
3. Sarwal MM, Yorgin PD, Alexander S et al. Promising early outcomes with a novel, complete steroid avoidance immunosuppression protocol in pediatric renal transplantation. Transplantation 2001: 72: 13.
4. Vidhun JR, Sarwal MM. Corticosteroid avoidance in pediatric renal transplantation: Can it be achieved? Paediatr Drugs 2004: 6: 273.
5. Vidhun JR,S arwal MM. Corticosteroid avoidance in pediatric renal transplantation. Pediatr Nephrol 2005: 20: 418.
6. Cole E, Landsberg D, Russell D et al. A pilot study of steroid-free immunosuppression in the prevention of acute rejection in renal allograft recipients. Transplantation 2001: 72: 845.
7. Kirk AD, Jacobson LM, Heisey DM, Fass NA, Sollinger HW, Pirsch JD. Posttransplant diastolic hypertension: Associations with intragraft transforming growth factor-beta, endothelin, and renin transcription. Transplantation 1997: 64: 1716.
8. Sarwal M, Chua MS, Kambham N et al. Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. N Engl J Med 2003: 349: 125.
9. Alizadeh A, Eisen M, Davis RE et al. The lymphochip: A specialized cDNA microarray for the genomic-scale analysis of gene expression in normal and malignant lymphocytes. Cold Spring Harb Symp Quant Biol 1999: 64: 71.
10. Sherlock G, Hernandez -Boussard T, Kasarskis A et al. The Stanford microarray database. Nucleic Acids Res 2001: 29: 152.
11. T usher VG, T ibshirani R, C hu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001: 98: 5116.
12. Tibshirani R, Hastie T, Narasimhan B, Chu G. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci USA 2002: 99: 6567.
13. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998: 95: 14863.
14. Page RD. TreeView: An application to display phylogenetic trees on personal computers. Comput Appl Biosci 1996: 12: 357.
15. ABI. PE Applied Biosystems, Method for Gene Expression Monitoring by Real-time PCR, Vol. 2, 1997. Applied Biosystems, Foster City, CA.
16. Keane MP, Belperio JA, Xue YY, Burdick MD, Strieter RM. Depletion of CXCR2 inhibits tumor growth and angiogenesis in a murine model of lung cancer. J Immunol 2004: 172: 2853.
17. Slupsky JR, Seehafer JG, Tang SC, Masellis -Smith A, Shaw AR. Evidence that monoclonal antibodies against CD9 antigen induce specific association between CD9 and the platelet glycoprotein IIb-IIIa complex. J Biol Chem 1989: 264: 12289.
18. Goh EL, Zhu T, Leong WY, Lobie PE. c-Cbl is a negative regulator of GH-stimulated STAT5-mediated transcription. Endocrinology 2002: 143: 3590.
19. Joazeiro CA, Wing SS, Huang H, Leverson JD, Hunter T, Liu YC. The tyrosine kinase negative regulator c-Cbl as a RING-type, E2-dependent ubiquitin-protein ligase. Science 1999: 286: 309.
20. Moon AM, Guris DL, Seo JH et al. Crkl deficiency disrupts Fgf8 signaling in a mouse model of 22q11 deletion syndromes. Dev Cell 2006: 10: 71.
21. Yorgin PD, Belson A, Sanchez J et al. Unexpectedly high prevalence of posttransplant anemia in pediatric and young adult renal transplant recipients. Am J Kidney Dis 2002: 40: 1306.
22. Kausman JY, Powell HR, J ones CL. Anemia in pediatric renal transplant recipients. Pediatr Nephrol 2004: 19: 526.
23. Krstic C, Radojicic B. Prednisone therapy in patients with pernicious anemia (report of 2 cases). Bilt Hematol Transfuz 1977: 5: 69.
24. Brines M, Cerami A. Discovering erythropoietin's extra-hematopoietic functions: Biology and clinical promise. Kidney Int 2006: 70: 246.
25. Singbartl G. Adverse events of erythropoietin in long-term and in acute/ short-term treatment. Clin Invest 1994: 72: S36.
26. Tobu M, Iqbal O, Fareed D et al. Erythropoietin-induced thrombosis as a result of increased inflammation and thrombin activatable fibrinolytic inhibitor. Clin Appl Thromb Hemost 2004: 10: 225.
27. Dale GL, Alberio L. Is there a correlation between raised erythropoietin and thrombotic events in sickle-cell anaemia? Lancet 1998: 352: 566.
28. Fuste B, Diaz -Ricart M, Cases A, Lopez -Pedret J, Ordinas A, Escolar G. Erythropoietin does not modify the prothrombotic effect induced by uremic media on endothelial cells. Haematologica 2002: 87: 1006.
29. Fuste B, Serradell M, Escolar G et al. Erythropoietin triggers a signaling pathway in endothelial cells and increases the thrombogenicity of their extracellular matrices in vitro. Thromb Haemost 2002: 88: 678.
30. Aguilera A, Selgas R, Ruiz -Caravaca ML et al. Effects of recombinant human erythropoietin on functional and injury endothelial markers in peritoneal dialysis patients. Perit Dial Int 1999: 19 (Suppl. 2): S161.
31. Carlini RG, Gupta A, Liapis H, Rothstein M. Endothelin-1 release by erythropoietin involves calcium signaling in endothelial cells. J Cardiovasc Pharmacol 1995: 26: 889.
32. N eff MS, K im KE, P ersoff M, O nesti G, S wartz C. Hemodynamics of uremic anemia. Circulation 1971: 43: 876.
33. Bode -Boger SM, Boger RH, Kuhn M, Radermacher J, Frolich JC. Recombinant human erythropoietin enhances vasoconstrictor tone via endothelin-1 and constrictor prostanoids. Kidney Int 1996: 50: 1255.
34. M artin J, M oncada S. Blood pressure, erythropoietin, and nitric oxide. Lancet 1988: 1: 644.
35. Steffen HM, Brunner R, Muller R et al. Peripheral hemodynamics, blood viscosity, and the renin-angiotensin system in hemodialysis patients under therapy with recombinant human erythropoietin. Contrib Nephrol 1989: 76: 292.
36. K aizuT, Nakao A, Tsung A et al. Carbon monoxide inhalation ameliorates cold ischemia/reperfusion injury after rat liver transplantation. Surgery 2005: 138: 229.
37. Melderis H, Steinheider G, Ostertag W. Evidence for a unique kind of alpha-type globin chain in early mammalian embryos. Nature 1974: 250: 774.
38. Papayannopoulou T, Nakamoto B, Anagnou NP, Chui D, Dow L, Sanders J. Expression of embryonic globins by erythroid cells in juvenile chronic myelocytic leukemia. Blood 1991: 77: 2569.
39. Oda A, Sawada K, Druker BJ et al. Erythropoietin induces tyrosine phosphorylation of Jak2, STAT5A, and STAT5B in primary cultured human erythroid precursors. Blood 1998: 92: 443.
40. Barber DL, Mason JM, Fukazawa T et al. Erythropoietin and interleukin-3 activate tyrosine phosphorylation of CBL and association with CRK adaptor proteins. Blood 1997: 89: 3166.
41. Arai A, Kanda E, Nosaka Y, Miyasaka N, Miura O. CrkL is recruited through its SH2 domain to the erythropoietin receptor and plays a role in Lyn-mediated receptor signaling. J Biol Chem 2001: 276: 33282.
42. Longmore GD, You Y, Molden J et al. Redundant and selective roles for erythropoietin receptor tyrosines in erythropoiesis in vivo. Blood 1998: 91: 870.
43. Joneja B, Chen HC, Seshasayee D, Wrentmore AL, Wojchowski DM. Mechanisms of stem cell factor and erythropoietin proliferative co-signaling in FDC2-ER cells. Blood 1997: 90: 3533.
44. Odai H, Sasaki K, Hanazono Y et al. c-Cbl is inducibly tyrosine-phosphorylated by epidermal growth factor stimulation in fibroblasts, and constitutively tyrosine-phosphorylated and associated with v-Src in v-src-transformed fibroblasts. Jpn J Cancer Res 1995: 86: 1119.
45. Galisteo ML,D ikic I, Batzer AG, Langdon WY, Schlessinger J. Tyrosine phosphorylation of the c-cbl proto-oncogene protein product and association with epidermal growth factor (EGF) receptor upon EGF stimulation. J Biol Chem 1995: 270: 20242.
46. D uval M, B edard -G oulet S, D elisle C, G ratton JP. Vascular endothelial growth factor-dependent down-regulation of Flk-1/KDR involves Cbl-mediated ubiquitination. Consequences on nitric oxide production from endothelial cells. J Biol Chem 2003: 278: 20091.